Drugs / capetabine
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT06304987 Background | Apr 2024 → Apr 2026 | — | Beijing Friendship Hospital | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | capetabine | “Simultaneously receive 30 days of capetabine treatment at weeks 1-2, weeks 3-5, and weeks 6-8, 825-1000mg/m2, bid, po, days 1-5/week” NCT06304987 ↗ |
| Route | Oral | “825-1000mg/m2, bid, po, days 1-5/week” NCT06304987 ↗ |